Categories Earnings, Technology
Palo Alto Networks (PANW) Q1 earnings preview: Billings to dominate amid costs threat
Cybersecurity firm Palo Alto Networks Inc. (NYSE: PANW) is set to release its first-quarter 2020 earnings results on Monday, November 25, after the market closes. The top line will be benefited by billings growth, which is likely to soar above the billion-mark.
However, the bottom line will be impacted by the costs and expenses that will be incurred due to its investments in the research and development of new hardware and software development. The hardware and software are both critical in expanding its leadership in the enterprise security market. The rapidly changing applications and threat landscape will allow the company to focus on research.
The company relies on new offerings such as cloud security, artificial intelligence, and analytics offerings for future success. However, the market for enterprise security products is intensely competitive that is likely to increase in the future from established competitors and new market entrants.
Analysts expect the company’s earnings to drop by 12% to $1.03 per share while revenue will jump by 17% to $767.86 million for the first quarter. The company has surprised investors by beating analysts’ expectations in all of the past four quarters. The majority of the analysts recommended a “buy” rating with an average price target of $264.14.
For the fourth quarter, Palo Alto slipped to a loss from a profit last year, due to higher costs and expenses. The top-line growth was driven by a 22% jump in the total billings that crossed the billion-mark for the first time. The company achieved about 180% year-over-year growth in its newer Prisma and Cortex offerings.
For the first quarter, the company expects billings growth of 15% to 17% year-over-year and revenue growth of 16% to 17%. Adjusted earnings are anticipated to be $1.02 to $1.04 per share for the first quarter. For fiscal 2020, Palo Alto predicts billings growth of 17% to 19%, revenue growth of 19% to 20%, and adjusted earnings of $5.00 to $5.10 per share.
Get access to timely and accurate verbatim transcripts that are published within hours of the event.
Most Popular
Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO
Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical biotechnology company engaged in the discovery development, and commercialization of first-in-class cancer drugs that attenuate tumors with minimal side effects while training
What to expect when J.M. Smucker (SJM) reports Q2 2025 earnings results
Shares of The J.M. Smucker Co. (NYSE: SJM) stayed red on Friday. The stock has dropped 6% over the past three months. The branded foods company is slated to report
Earnings Summary: Highlights of BJ’s Wholesale Club’s Q3 2024 results
Department store chain BJ’s Wholesale Club Holdings, Inc. (NYSE: BJ) has reported financial results for the third quarter of 2024, reporting a 3% increase in net sales. Adjusted earnings, on a